{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059104","form_type":"8-K","ticker":null,"cik":"0001442836","company_name":"Mersana Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.444071+00:00","generated_at":"2026-06-02T05:25:30.275178+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mersana Q1 net loss $19.3M ($0.16/shr); XMT-1660 Phase 1 ongoing, XMT-2056 resumed","bullets":["Net loss of $19.3M ($0.16/shr) vs $56.2M loss ($0.52) in Q1 2023; collaboration revenue $9.2M (up from $7.8M).","Cash, equivalents and securities $183.1M; expects runway into 2026.","XMT-1660 Phase 1 dose escalation continues; MTD not yet reached; initial data and expansion expected H2 2024.","XMT-2056 Phase 1 resumed enrollment after clinical hold lifted; dose escalation planned in 2024.","R&D expenses fell sharply to $18.7M from $47.3M driven by UpRi discontinuation and restructuring."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059104","json":"https://secwatch.observer/filing/0001104659-24-059104.json","markdown":"https://secwatch.observer/filing/0001104659-24-059104.md","text":"https://secwatch.observer/filing/0001104659-24-059104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924059104/0001104659-24-059104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924059104/tm2413939d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:25:30.275178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fefd75fd380166c22ae4890e8a3e3611b5fe4e58","claim":"Mersana Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $9.2 million, net income $19.3 million net loss, EPS $0.16 per share.","evidence_excerpt":"plan commitments into 2026. ● Net cash used in operating activities for the first quarter of 2024 was $32.7 million. · Collaboration revenue for the first quarter of 2024 was $9.2 million, compared to $7.8 million for the same period in 2023. The year-over-year change was primarily related to the company’s Johnson & Johnson collaboration, including both research","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924059104/0001104659-24-059104-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$9.2 million"},{"label":"Net income","value":"$19.3 million net loss"},{"label":"EPS","value":"$0.16 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}